

### **Non-executive Director**

Dr. Friedrich von Bohlen und Halbach (born 1962)

Dr. Friedrich von Bohlen und Halbach has been a board member of Cosmo Holding S.p.A. since 2005, elected on the list proposed by the investors in the private placement.

Dr. von Bohlen is managing partner at dievini Hopp BioTech Holding GmbH & Co. KG., the company managing the life science activities and investments of Dietmar Hopp.

He is a member of the following boards: chairman of the board (Beirat) of Apogenix GmbH, Heidelberg, member of the board of Cosmo Bioscience S.p.A., Lainate, Milan, member of the board of Curacyte AG, Munich, chairman of the Board (Beirat) of CureVac GmbH, Tübingen, member of the board (Beirat) of Cytonet GmbH & Co. KG, Weinheim, member of the board (Beirat) of febit Holding GmbH, Heidelberg, member of the board of febit Inc., Massachusetts (USA), Chairman of the board of Heidelberg Pharma AG, Heidelberg, member of the board (Beirat) of immatics GmbH, Tübingen, member of the board of Integrated Diagnostics Inc., Seattle (USA), chairman of the board of Life Biosystems AG, Basel, chairman of the board of Sygnis Pharma AG, Heidelberg, and member of the board of Wilex AG, Munich.

Dr. von Bohlen has more than 10 years of entrepreneurial experience in the Life Sciences. As former CEO of Lion Bioscience AG he led Lion's IPO in 2000 at 'Neuer Markt', Frankfurt and at Nasdaq, New York. In addition to that, he has been awarded numerous prizes, including the German Entrepreneur of the Year prize in 1999 by Ernst & Young, SAP and Manager Magazin.

Dr. von Bohlen holds a diploma in biochemistry from the University of Zurich and a PhD in neurobiology from the Swiss Federal Institute of Technology (ETH) in Zurich.